Fluoropyrrolidine

The demand for new drugs with both efficacy and safety in the therapeutic field of central nervous system diseases continues to rise. As the key structural parent nucleus of dipeptidyl peptidase 4 (DPP-4) inhibitor class antidiabetic drugs, fluoropyrrolidine can also be used as an important pharmaceutical intermediate to participate in the synthesis of a number of central nervous system drugs. Its mechanism of action is to target and regulate the biological activity of corresponding targets, reduce the excessive activation of related pathological pathways. It has a wide range of application space in the drug development of indications such as type 2 diabetes control and neuropathic pain relief, benefits hundreds of millions of patients with related diseases worldwide, and is a core structural unit that has attracted much attention in the field of small molecule drug research and development in recent years.

At present, the global market size of marketed drugs containing fluoropyrrolidine structure has exceeded 8 billion US dollars, and the compound annual growth rate from 2021 to 2025 is maintained at around 6.2%. From the perspective of competition pattern, European and American pharmaceutical enterprises have first-mover advantages in the research and development of innovative drugs related to this structure. As the relevant core patents expire successively, API enterprises in India and China are gradually expanding the capacity proportion of related intermediates and APIs. The number of domestic relevant API filings has increased by more than 120% in the past three years, and the promotion of centralized procurement policies has further accelerated the localization substitution process of this type of raw materials.

The core original research drugs related to fluoropyrrolidine were first developed by Merck. Among them, sitagliptin, as a representative original research drug, has the trade name Januvia. Its core compound patent expired in China in 2022. The main dosage form of the original research drug is tablet, with conventional specifications including 25mg, 50mg and 100mg, and it has been included in the *Catalogue of Chemical Reference Preparations* of China and the FDA reference preparation catalogue. Up to now, 12 enterprises in China have obtained CDE registration numbers for sitagliptin APIs, and more than 30 domestic sitagliptin preparations have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for fluoropyrrolidine-related APIs. Most products are in regular stock. Spot orders paid before 16:00 can be shipped on the same day. All products comply with multiple regulatory standards such as Chinese Pharmacopoeia and FDA, and can fully meet the reference substance needs of each link such as API research and development, quality study, and production release.